✦ LIBER ✦

Phase II Trial of a Toll-Like Receptor 9-Activating Oligonucleotide in Patients With Metastatic Melanoma

✍ Scribed by Pashenkov, M.; Goess, G.; Wagner, C.; Hormann, M.; Jandl, T.; Moser, A.; Britten, C. M.; Smolle, J.; Koller, S.; Mauch, C.; Tantcheva-Poor, I.; Grabbe, S.; Loquai, C.; Esser, S.; Franckson, T.; Schneeberger, A.; Haarmann, C.; Krieg, A. M.; Stingl, G.; Wagner, S. N.

Book ID: 127321240
Publisher: American Society of Clinical Oncology
Year: 2006
Tongue: English
Weight: 777 KB
Volume: 24
Category: Article
ISSN: 0732-183X
DOI: 10.1200/jco.2006.07.9129

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II trial of arsenic trioxide in

A phase II trial of arsenic trioxide in patients with metastatic melanoma

✍ Kevin B. Kim; Agop Y. Bedikian; Luis H. Camacho; Nicholas E. Papadopoulos; Cecil 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 2 views

Phase II trial of imatinib mesylate in p

Phase II trial of imatinib mesylate in patients with metastatic melanoma

✍ Kim, K B; Eton, O; Davis, D W; Frazier, M L; McConkey, D J; Diwan, A H; Papadopo 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 305 KB

Phase II trial of fotemustine in patient

Phase II trial of fotemustine in patients with metastatic malignant melanoma

✍ Carla I. Falkson; Geoffrey Falkson; Hendré C. Falkson 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 318 KB

Phase II trial of hu14.18-IL2 for patien

Phase II trial of hu14.18-IL2 for patients with metastatic melanoma

✍ Mark R. Albertini, Jacquelyn A. Hank, Brian Gadbaw, Jordan Kostlevy, Jennifer Ha 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 319 KB

Intratumoural injection of the toll-like

Intratumoural injection of the toll-like receptor-2/6 agonist ‘macrophage-activating lipopeptide-2’ in patients with pancreatic carcinoma: a phase I/II trial

✍ Schmidt, J; Welsch, T; Jäger, D; Mühlradt, P F; Büchler, M W; Märten, A 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 205 KB

Outpatient combination chemoimmunotherap

Outpatient combination chemoimmunotherapy for patients with metastatic melanoma : Results of a Phase I/II trial

✍ Mohammed Kashani-Sabet; Richard W. Sagebiel; Henry E. Collins; Alan B. Glassberg 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 2 views

## BACKGROUND. Few studies have examined the feasibility, safety, and efficacy of an outpatient biochemotherapy regimen of low dose, subcutaneously administered interleukin-2 (IL-2) for patients with metastatic (Stage IV) melanoma. ## METHODS. Nineteen patients were treated with intravenous cispl